Screener
Immunovant, Inc. IMVT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Total assets | $957,014 | $776,222 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $7,541 | $17,656 |
| Accrued expenses | 96,634 | 50,748 |
| Current portion of operating lease liabilities | 72 | 98 |
| Due to Roivant Sciences Ltd. | 175 | 273 |
| Total current liabilities | 104,422 | 68,775 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s accounts payable?
- Immunovant, Inc. (IMVT) reported accounts payable of $7.54M in Q1 2026.
- How has Immunovant, Inc.'s accounts payable changed year-over-year?
- Immunovant, Inc.'s accounts payable decreased by 57.3% year-over-year, from $17.66M to $7.54M.
- What is the long-term trend for Immunovant, Inc.'s accounts payable?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s accounts payable has grown at a 25.4% compound annual growth rate (CAGR), from $2.43M to $7.54M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Immunovant, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude